Bor-Shiuan Shyr1, Bor-Uei Shyr1,2, Shih-Chin Chen1, Che-Chuan Loong2, Yi-Ming Shyr1, Shin-E Wang1. 1. Division of General Surgery, Department of Surgery, Taipei Veterans General Hospital, and National Yang Ming University, Taipei. 2. Division of Transplant Surgery, Department of Surgery, Taipei Veterans General Hospital, and National Yang Ming University, Taipei.
Abstract
BACKGROUND: Pancreas transplantation remains the best long-term treatment option to achieve physiological euglycemia and insulin independence in patients with labile diabetes mellitus (DM). It is widely accepted as an optimal procedure for type 1 DM (T1DM), but its application in type 2 DM (T2DM) is not unanimously acknowledged. METHODS: In total, 146 diabetes patients undergoing pancreas transplantation were included in this study. Clinical data and outcomes were compared between the T1DM and T2DM groups. RESULTS: Majority (93%) of the pancreas transplantations in T2DM were for uremic recipients. Complications occurred in 106 (73%) patients, including 70 (48%) with early complications before discharge and 79 (54%) with late complications during follow-up period. Overall, rejection of pancreas graft occurred in 37 (25%) patients. Total rejection rate in T2DM recipients was significantly lower than that in T1DM. The short- and long-term outcomes for endocrine function in terms of fasting blood sugar and hemoglobin A1c levels and graft survival rates are comparable between the T2DM and T1DM groups. CONCLUSIONS: T2DM is not inferior to T1DM after pancreas transplantation in terms of surgical risks, immunological and endocrine outcomes, and graft survival rates. Therefore, pancreas transplantation could be an effective option to treat selected uremic T2DM patients without significant insulin resistance. 2021 Hepatobiliary Surgery and Nutrition. All rights reserved.
BACKGROUND: Pancreas transplantation remains the best long-term treatment option to achieve physiological euglycemia and insulin independence in patients with labile diabetes mellitus (DM). It is widely accepted as an optimal procedure for type 1 DM (T1DM), but its application in type 2 DM (T2DM) is not unanimously acknowledged. METHODS: In total, 146 diabetes patients undergoing pancreas transplantation were included in this study. Clinical data and outcomes were compared between the T1DM and T2DM groups. RESULTS: Majority (93%) of the pancreas transplantations in T2DM were for uremic recipients. Complications occurred in 106 (73%) patients, including 70 (48%) with early complications before discharge and 79 (54%) with late complications during follow-up period. Overall, rejection of pancreas graft occurred in 37 (25%) patients. Total rejection rate in T2DM recipients was significantly lower than that in T1DM. The short- and long-term outcomes for endocrine function in terms of fasting blood sugar and hemoglobin A1c levels and graft survival rates are comparable between the T2DM and T1DM groups. CONCLUSIONS: T2DM is not inferior to T1DM after pancreas transplantation in terms of surgical risks, immunological and endocrine outcomes, and graft survival rates. Therefore, pancreas transplantation could be an effective option to treat selected uremic T2DM patients without significant insulin resistance. 2021 Hepatobiliary Surgery and Nutrition. All rights reserved.
Entities:
Keywords:
Type 2 diabetes mellitus (T2DM); pancreas; transplantation
Authors: G E Gondolesi; N F Aguirre; D A Ramisch; F A Mos; N F Pedraza; M R Fortunato; L M Gutiérrez; H Fraguas; R Marrugat; G E Rabin; C Musso; P A Farinelli; P H L Barros Schelotto; P M Raffaele Journal: Transplant Proc Date: 2018-03-12 Impact factor: 1.066
Authors: R Kandaswamy; P G Stock; S K Gustafson; M A Skeans; M A Curry; M A Prentice; A Fox; A K Israni; J J Snyder; B L Kasiske Journal: Am J Transplant Date: 2018-01 Impact factor: 8.086
Authors: H A Chakkera; J K Bodner; R L Heilman; D C Mulligan; A A Moss; K L Mekeel; M J Mazur; K Hamawi; R M Ray; G L Beck; K S Reddy Journal: Transplant Proc Date: 2010-09 Impact factor: 1.066
Authors: R Kandaswamy; P G Stock; S K Gustafson; M A Skeans; M A Curry; M A Prentice; A K Israni; J J Snyder; B L Kasiske Journal: Am J Transplant Date: 2017-01 Impact factor: 8.086
Authors: Christian Margreiter; Thomas Resch; Rupert Oberhuber; Felix Aigner; Herbert Maier; Robert Sucher; Stefan Schneeberger; Hanno Ulmer; Claudia Bösmüller; Raimund Margreiter; Johann Pratschke; Robert Öllinger Journal: Transplantation Date: 2013-04-27 Impact factor: 4.939